Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML.
Blood Adv. 2019 Aug 13;3(15):2307-2311
Mobilization of leukemic cells using plerixafor as part of a myeloablative preparative regimen for patients with AML undergoing allografting: assessment of safety and tolerability.
Biol Blood Marrow Transplant. 2019 Jan 14;:
Biol Blood Marrow Transplant. 2019 Jan 06;:
A phase II open-label study of aprepitant as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy.
Support Care Cancer. 2018 Oct 19;:
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN-Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community.
Curr Hematol Malig Rep. 2018 Oct 18;:
The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes.
Blood Adv. 2018 Oct 23;2(20):2658-2671
Clin Lymphoma Myeloma Leuk. 2018 Aug 31;:
Distinct patterns of clonal evolution in patients with concurrent myelo- and lymphoproliferative neoplasms.
Blood. 2018 Sep 24;:
Ruxolitinib Therapy Followed by Reduced Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis - Myeloproliferative Disorders Research Consortium 114 study.
Biol Blood Marrow Transplant. 2018 Sep 08;:
Am J Gastroenterol. 2018 Aug 30;: